COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Recycling Rules Without Proof Are Just Non-Negotiable Paper; SMX Turns Them Into Tradable Currency (NASDAQ: SMX)
SMX introduces molecular proof technology to enforce regulations at scale, bridging the enforcement gap seen in sustainability policies. Collaboration with Singapore, Europe, and North America showcases its impact on recycling, safety standards, and governance -
COMMUNIQUÉ DE PRESSE
Leonardo Art Holdings GmbH submits specified squeeze-out request and sets cash compensation for the transfer of the shares held by the minority share-holders of artnet AG at EUR 11.16
Leonardo Art Holdings GmbH submits squeeze-out request for artnet AG, setting cash compensation at EUR 11.16 per share. Majority Shareholder holds 95.42% share capital -
-
COMMUNIQUÉ DE PRESSE
The SIM Card Attack No One's Ready For - And the SMX Technology That Can Stop It (NASDAQ: SMX)
SMX (Security Matters, NASDAQ:SMX) offers a platform embedding molecular markers into materials to provide proof before panic, preventing escalation in security threats. Learn how SMX transforms supply chains to fortresses -
COMMUNIQUÉ DE PRESSE
FUCHS takes over its long-standing Swiss distribution partner ASEOL SUISSE AG and further expands market presence
FUCHS Group acquires ASEOL SUISSE AG, expanding market presence by merging with FUCHS SWISS LUBRICANTS AG. Transaction aims to strengthen Swiss market position and offer comprehensive solutions to various industries -
COMMUNIQUÉ DE PRESSE
Join FatPipe's Exclusive Live Investor Webinar and Q&A Session on October 15
FatPipe, Inc. invites investors to a webinar on Oct 15, 2025, featuring its Chairman & CEO discussing the company's leadership in SD-WAN & cybersecurity markets with strong financial performance and global expansion plans -
-
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Mainz Biomed reports positive topline results from feasibility study of biomarker panel for pancreatic cancer detection, achieving 100% sensitivity and 95% specificity. The study paves the way for a reliable, non-invasive screening test
